SynthesisPloS one2013
Statins and the risk of lung cancer: a meta-analysis.
Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Role of statins in non-small cell lung cancer treatment: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials.Drug design, development and therapy · 2019Pooled it
- Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis.Lipids in health and disease · 2015Pooled it
- Statins are associated with reduced risk of gastric cancer: a meta-analysis.European journal of clinical pharmacology · 2013Pooled it
- Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.Journal of clinical medicine · 2025Review
- Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer.International journal of molecular sciences · 2023Review
- Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role.Pharmaceuticals (Basel, Switzerland) · 2022Review
- A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study.JNCI cancer spectrum · 2021Article
- Article
- Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis.Journal of clinical medicine · 2019Article
- Statin drugs to reduce breast cancer recurrence and mortality.Breast cancer research : BCR · 2018Review
- Diabetes, Obesity, and Breast Cancer.Endocrinology · 2018Review
- The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials.Journal of clinical medicine · 2018Article
- Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective.Oncotarget · 2017Review
- Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.International journal of molecular sciences · 2017Review
- Smoking, depression, and hospital costs of respiratory cancers: Examining race and sex variation.Family medicine and community health · 2017Article
- Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?Current atherosclerosis reports · 2016Review
- Repurposing of approved cardiovascular drugs.Journal of translational medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeveral epidemiologic studies have evaluated the association between statins and lung cancer risk, whereas randomized controlled trials (RCTs) on cardiovascular outcomes provide relevant data as a secondary end point. We conducted a meta-analysis of all relevant studies to examine this association.
methodsA systematic literature search up to March 2012 was performed in PubMed database. Study-specific risk estimates were pooled using a random-effects model.
resultsNineteen studies (5 RCTs and 14 observational studies) involving 38,013 lung cancer cases contributed to the analysis. They were grouped on the basis of study design, and separate meta-analyses were conducted. There was no evidence of an association between statin use and risk of lung cancer either among RCTs (relative risk [RR] 0.91, 95% confidence interval [CI] 0.76-1.09), among cohort studies (RR 0.94, 95% CI 0.82-1.07), or among case-control studies (RR 0.82, 95% CI 0.57-1.16). Low evidence of publication bias was found. However, statistically significant heterogeneity was found among cohort studies and among case-control studies. After excluding the studies contributing most to the heterogeneity, summary estimates were essentially unchanged.
conclusionThe results of our meta-analysis suggest that there is no association between statin use and the risk of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.